4 compelling reasons against Mental Health Parity Fri, 12 Sep 2003 Compelling reasons NOT to approve insurance parity for mental health services come from the following recent reports suggesting that mental health services and treatments have often done more damage than good. Until psychiatry and mental health service providers develop…
To view AHRP news and infomails from 2006, please visit our new site. Infomails Subscribe to AHRP’s infomails At FDA, Graham is still the whistle-blower Loss of Trust: Big Drug Makers See Sales Decline With Their Image War hero’s death in clinical trial follows years of FDA neglect European perspective:…
AHRP Speaks Out AHRP Press Briefing 9/14/04: Antidepressants & suicide-related risks for children Open Letter to NIMH re Prozac & Concealed Suicide Attempts Open Letter to Officials at NIMH AHRP Briefing 2/2/04: Scientists present suicide evidence Conflicts of Interest policy – New York Times Phase I Drug Trials Used Foster…
AHRP Campaign to Protect Children from Harm Oct 15: FDA Orders Black Box Warnings on Antidepressants labels and Patient Information Guides to Warn about Suicide risk Oct 3: BBC PANORAMA TONIGHT – Taken on Trust – 13 years-Medical Deception Sep 30: GSK Sales Reps told NOT to Divulge Paxill Data…
Protecting Human Subjects in Research: Are Current Safeguards Adequate? AHRP Testimony submitted to Congressional Committee April 23, 2002 Vera Hassner Sharav, President, and John H. Noble, Jr., Ph.D., steering committee member, The Alliance for Human Research Protection (AHRP), before the Subcommittee on Public Health, Committee on Health, Education, Labor, &…
Dr. Kramer – All Things They Taught Us That Were Wrong in Psychiatry Thu, 15 Sep 2005 In a 2004 column, a psychiatrist who engages in “myth busting” inadvertently confirms that psychiatry is given to prescribing mood swings. He acknowledges that sometimes effective treatments are dropped (benzodiazepines) for new ones…
Medscape Cites AHRP Concerns Re: New Law Mandates More Testing of Drugs in Children Wed, 17 Dec 2003 Medscape Medical News reports about passage of the Pediatric Research Equity Act (PREA) which replaces FDA’s Pediatric Rule. The Pediatric Rule was struck down by a Federal court in Oct. 2002 because…
Are SSRIs and Atypical Antidepressants Safe / Effective for Children / Adolescents/ Neonates? Wed, 2 Mar 2005 The American psychiatric establishment continues to operate within a “head in the sand” culture of denial when confronted with compelling evidence that has been scientifically replicated showing that their prescribing of antidepressants for…
Pharma’s Pervasive Influence Corrupts Medicine both sides of Atlantic Tue, 4 Oct 2005 The focus of criticism in medicine has shifted from cost and barriers to access to treatments to an examination of the safety and benefit of current treatments. The pharmaceutical industry’s corrupting influence on physicians, academic researchers, the…
Industry’s blockbuster sellers–the atypical antipsychotics performed WORSE than their cheaper, non-patented precursors.
Psychiatry’s professional practice paradigm has received a major blow.
“Medication-Free Research in Early Episode Schizophrenia: Evidence of Long-Term Harm?” An article in the Schizophrenia Bulletin, by Dr. John Bola that dares to question the validity of the unexamined treatment paradigm in schizophrenia:
